Dipeptidylpeptidase-4 inhibitors (?gliptins?): risk of acute pancreatitis

[Northerner]

There have been reports of acute pancreatitis associated with drugs in the dipeptidylpeptidase-4 (DPP-4) inhibitor class of antidiabetic agents (?gliptins?). Patients should be informed of the characteristic symptoms of acute pancreatitis ? persistent, severe abdominal pain (sometimes radiating to the back) ? and encouraged to tell their healthcare provider if they have such symptoms. If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicinal products should be discontinued.

http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON185628